WebIn connection to the directed issue that was completed in September 2024 a total of 34,519,281 warrants of series TO2 was issued. Each warrant of series TO2 will give the holder the right to subscribe for one new share of series B in Cereno during the period from 14 September 2024 until and including 28 September 2024 to a subscription price ... WebApr 5, 2024 · Born 1953. Björn Dahlöf is Cereno’s Chief Medical Officer since 2024 and has for many years been an adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management studies after registration. Björn Dahlöf has extensive experience in cardiovascular …
CERENO SCIENTIFIC AB (PUBL) - MarketScreener.com
WebApr 3, 2024 · Cereno has a project portfolio targeting common and rare cardiovascular diseases. The aim is to develop treatments that can improve the life for affected patients. The portfolio comprises a Phase II program and two preclinical programs. Read more. … Cereno Scientific is a clinical-stage biotech company within common and rare … Therapeutic focus. Cereno focuses on epigenetic modulation in cardiovascular … 16th Global Cardiovascular Clinical Trialists Forum Faiez Zannad and Bertram Pitt, … Cereno Scientific is a biotech company focusing on developing innovative … The extraordinary General Meeting of Cereno Scientific AB (Publ) took place … Career. Cereno Scientific is a clinical-stage biotech company within common and … Cereno Scientific AB BioVentureHub Pepparedsleden 1 431 83 Mölndal, … BIO-Europe 2024 Cereno Scientific will attend BIO-Europe 2024. Contact Sten … 16th Global Cardiovascular Clinical Trialists Forum Faiez Zannad and Bertram Pitt, … WebFeb 28, 2024 · Cereno Scientific AB (publ), clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. Its lead drug candidate is CS1, a product candidate that is in Phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension and thrombotic indications. chase bank northgate seattle
Contact us for more information Cereno Scientific
WebDec 10, 2024 · Cereno Scientifics aim is to form a platform of drug candidates that affects the field of epigenetic modulation through "HDAC inhibition" (Histone DeACetylase inhibition). The company's first program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. WebDefinition of cereno in the Definitions.net dictionary. Meaning of cereno. What does cereno mean? Information and translations of cereno in the most comprehensive … WebDeveloping innovative treatments for patients affected by common and rare cardiovascular diseases. Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. curtin humanitarian fund scholarship